Activation of interferon-inducible genes in mice by poly rI:rC or alloantigens.
We have examined the effects of synthetic dsRNA (poly rI:rC) treatment or of immunization with irradiated allogeneic cells on the expression in vivo of several interferon (IFN)-inducible genes. For this purpose, DBA/2 mice were injected i.p. once with poly rI:rC, or once and then again 3 weeks later, with irradiated C3H/He spleen cells and the effect of these treatments on the levels of the following mRNAs was determined: 202, 2',5'-oligoadenylate synthetase (2-5A synthetase), class I and class II major histocompatibility antigens, and beta-actin. After poly rl:rC treatment, the levels of the 202 and 2-5A synthetase mRNAs in the spleen and in the bone marrow peaked between 12 and 24 h and decreased thereafter. The class I mRNA levels started to increase at 12 h, peaked at 24 h, and declined thereafter. No increase in class II mRNA expression was observed after poly rl:rC injection, whereas beta-actin levels remained unchanged. Pretreatment of DBA/2 mice with sheep anti-murine IFN-alpha/beta antibodies before poly rI:rC injection strongly diminished the induction of 202 mRNA, indicating that IFN-alpha/beta mediated this induction. When irradiated C3H/He spleen cells were injected into DBA/2 mice, the class I and class II mRNAs in the spleen, but not in the bone marrow, started to increase at 12 h, peaked between 48 and 96 h, and decreased thereafter. No increase in the levels of 202 and 2-5A synthetase mRNAs was detected, whereas beta-actin levels remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
Gariglio
M
M
Institute of Microbiology, Medical School, University of Torino, Italy.
Cinato
E
E
Panico
S
S
Cavallo
G
G
Landolfo
S
S
D015088:2',5'-Oligoadenylate Synthetase / Q000235:genetics; D000818:Animals; D001853:Bone Marrow / Q000378:metabolism; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007114:Immunization; D007116:Immunization, Passive; D007370:Interferon Type I / Q000096:biosynthesis / Q000276:immunology / Q000494:pharmacology; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology / Q000494:pharmacology; D007372:Interferons / Q000096:biosynthesis / Q000494:pharmacology*; D007519:Isoantigens / Q000276:immunology*; D007700:Kinetics; D051379:Mice; D008809:Mice, Inbred C3H; D008811:Mice, Inbred DBA; D011070:Poly I-C / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D013154:Spleen / Q000276:immunology
D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D007370:Interferon Type I; D007519:Isoantigens; D012333:RNA, Messenger; D007371:Interferon-gamma; D007372:Interferons; D015088:2',5'-Oligoadenylate Synthetase; D011070:Poly I-C